Sodium polystyrene sulfonate (SPS or Kayexalate), a treatment for hyperkalemia, was approved by the FDA in 1958, which was before the time the FDA required safety and efficacy reporting for drug approval. In 2009, the FDA issued a warning about the association of kayexalate-sorbitol use (which is the common preparation used in the US) due to reports of colonic necrosis. This study reviewed efficacy data for kayexalate-sorbitol and found no convincing evidence that it significantly lowers serum potassium. Given the lack of efficacy data, and recent reports of harm, we should question our use of this drug in hospitalized patients (abstract)
|
June 11, 2010 |
0 
Share This Post
About the Author: Danielle Scheurer
Danielle Scheurer, MD, MSCR, SFHM is a clinical hospitalist and the Chief Quality Officer at the Medical University of South Carolina in Charleston, South Carolina, where she also serves as Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She is also the President of SHM's Board of Directors and previously served as Physician Editor of The Hospitalist, SHM's monthly newsmagazine.
Categories
Related Posts
November 8, 2019 |
0Do you have a stack of journals piling up on your desk, beside your bed or in your email inbox? In 1950, medical knowledge was estimated to double every 50 years, but now the doubling time is every few months. At this rate, it is impossible to keep up with the literature, but a group […]
June 29, 2013 |
0This large systematic review found rectal NSAIDs significantly reduced the risk of post-ERCP pancreatitis compared to pancreatic duct stents (abstract).
June 22, 2013 |
0This large population-based cohort found the most common causes of drug induced liver injury to be augmentin and diclofenac, followed by herbal and nutritional supplements (abstract).
Leave A Comment